We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bioverativ Inc. today announced that the first patient has been dosed in the Phase 3 clinical program of its investigational therapy BIVV009 for cold agglutinin disease (CAgD)
Strengthens leadership in rare blood disorders with first-in-class candidate to treat cold agglutinin disease, a chronic autoimmune hemolytic anemia with no approved therapies.